213 related articles for article (PubMed ID: 32337896)
1. DAS28-ESR and DAS28-CRP - are they Interchangeable in Measuring the Activity of Rheumatoid Arthritis in Response to Treatment with Biological Agents?
Shivacheva TK
Folia Med (Plovdiv); 2020 Mar; 62(1):46-51. PubMed ID: 32337896
[TBL] [Abstract][Full Text] [Related]
2. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
Wells G; Becker JC; Teng J; Dougados M; Schiff M; Smolen J; Aletaha D; van Riel PL
Ann Rheum Dis; 2009 Jun; 68(6):954-60. PubMed ID: 18490431
[TBL] [Abstract][Full Text] [Related]
3. Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
Plant D; Ibrahim I; Lunt M; Eyre S; Flynn E; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; ; Barton A
Arthritis Res Ther; 2012 Oct; 14(5):R214. PubMed ID: 23039402
[TBL] [Abstract][Full Text] [Related]
4. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis.
Sengul I; Akcay-Yalbuzdag S; Ince B; Goksel-Karatepe A; Kaya T
Int J Rheum Dis; 2015 Jul; 18(6):640-5. PubMed ID: 26013310
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the disease activity score using the erythrocyte sedimentation rate and C-reactive protein levels in Koreans with rheumatoid arthritis.
Son KM; Kim SY; Lee SH; Yang CM; Seo YI; Kim HA
Int J Rheum Dis; 2016 Dec; 19(12):1278-1283. PubMed ID: 26200604
[TBL] [Abstract][Full Text] [Related]
8. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).
Ramiro S; Landewé RB; van der Heijde D; Sepriano A; FitzGerald O; Ostergaard M; Homik J; Elkayam O; Thorne JC; Larche M; Ferraccioli G; Backhaus M; Boire G; Combe B; Schaeverbeke T; Saraux A; Dougados M; Rossini M; Govoni M; Sinigaglia L; Cantagrel AG; Allaart CF; Barnabe C; Bingham CO; Tak PP; van Schaardenburg D; Hammer HB; Dadashova R; Hutchings E; Paschke J; Maksymowych WP
Ann Rheum Dis; 2020 Apr; 79(4):453-459. PubMed ID: 32094157
[TBL] [Abstract][Full Text] [Related]
9. Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis.
Kuriya B; Schieir O; Lin D; Xiong J; Pope J; Boire G; Haraoui B; Thorne JC; Tin D; Hitchon C; Jamal S; Keystone E; Bykerk VP;
Clin Exp Rheumatol; 2017; 35(5):799-803. PubMed ID: 28339365
[TBL] [Abstract][Full Text] [Related]
10. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
[TBL] [Abstract][Full Text] [Related]
11. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
Roodenrijs NMT; de Hair MJH; Wheater G; Elshahaly M; Tekstra J; Teng YKO; Lafeber FPJG; Hwang CC; Liu X; Sasso EH; van Laar JM
Arthritis Res Ther; 2018 Nov; 20(1):256. PubMed ID: 30458871
[TBL] [Abstract][Full Text] [Related]
12. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
Kizaki K; Yamashita F; Hayashi T; Funakoshi N
Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
[TBL] [Abstract][Full Text] [Related]
13. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.
Hirata S; Saito K; Kubo S; Fukuyo S; Mizuno Y; Iwata S; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
Arthritis Res Ther; 2013 Sep; 15(5):R135. PubMed ID: 24286472
[TBL] [Abstract][Full Text] [Related]
15. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ
Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: A single-center experience in Taiwan.
Wang KC; Liao HT; Chen WS; Lai CC; Chou CT; Chen MH; Tsai CY
Int J Rheum Dis; 2019 May; 22(5):860-868. PubMed ID: 30761753
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study.
Nishimoto N; Takagi N
Mod Rheumatol; 2010 Dec; 20(6):539-47. PubMed ID: 20617358
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice.
Mochizuki T; Yano K; Ikari K; Hiroshima R; Takaoka H; Kawakami K; Koenuma N; Shirahata T; Momohara S
Mod Rheumatol; 2016 Jul; 26(4):499-506. PubMed ID: 26473281
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
[TBL] [Abstract][Full Text] [Related]
20. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
